drugset / Trial / NCT00658658
Panitumumab in Children With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study was to evaluate the safety and pharmacokinetics of up to 3 different dose schedules of panitumumab in pediatric patients with solid tumors.
Timeline
- Start
- 2008-03
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Panitumumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Panitumumab | Monoclonal antibody | 9 mg/kg | Intravenous |